ArticleJournal of translational medicine2026
Nrf2 overexpression reprograms neural stem cell fate: promoting neuronal differentiation and functional recovery post-ischemic stroke via suppression of the ROS/NF-κB axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exercise Improves Mitochondrial Homeostasis: A Potential Neuroprotective Strategy for Ischemic Stroke.Antioxidants (Basel, Switzerland) · 2026Review
- Delphinidin-3-O-glucoside attenuates neonatal hypoxic-ischemic encephalopathy in a neonatal mouse model by reprogramming microglial polarization.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundNeural stem cells (NSCs) have been experimentally used in multiple models and patients, offering great potential for the treatment of neurological disorders such as ischaemic stroke. However, the proliferative and differentiative limitations of NSCs transplants must be overcome to further exploit the clinical potential of NSCs-based therapies.
objectiveThis study aimed to elucidate the regulatory role of Nrf2 in NSCs proliferation and neuronal differentiation in vitro, to evaluate the therapeutic potential of transplanting Nrf2-overexpressed NSCs for functional recovery in the MCAO mouse model, and to further explore the synergistic benefits of combining this cell therapy with the pharmacological Nrf2 agonist PTE.
methodsThe study design encompassed in vitro NSC cultures and a mouse MCAO model, involving Nrf2 modulation, transplantation of engineered NSCs, pharmacological activation with PTE, and comprehensive assessment of cellular, molecular, and functional outcomes. Specifically, Nrf2 expression was manipulated using AAV-9. Nrf2-overexpressed NSCs were generated via AAV-9 transduction and stereotaxically transplanted into the lateral ventricle of mice with MCAO, with a subset of these animals additionally receiving the Nrf2 agonist PTE. Nestin, Dcx, BrdU, NeuN, and GFAP expression were evaluated using immunofluorescence; GFAP-positive and NeuN-positive cell proportions were quantified by flow cytometry. Oxidative stress was monitored using DCF fluorescence and MDA ELISA kits. Inflammation was measured with IL-6 and TNF-α ELISA kits. The expression levels of Nrf2, HO-1, NQO1, p65, and NLRP3 were evaluated using western blotting. Neurological deficits were assessed using Clark scores, rotarod test, Morris water maze, grip strength test, cerebral water content measurement, and TTC staining for infarction volume.
resultsOverexpression or knockdown of Nrf2 in vitro (in NSCs) and in vivo (in mouse hippocampus) correspondingly regulated the expression of its downstream effectors, HO-1 and NQO1. In vitro, Nrf2 regulated the proliferation and neuronal differentiation of NSCs. In the MCAO mouse model, Nrf2 ameliorated cerebral oxidative stress and inflammation, and improved functional recovery, as evidenced by improved neurological scores, enhanced performance in behavioural tests, reduced infarction volume, and attenuated cerebral oedema. Transplantation of Nrf2-overexpressed NSCs promoted the proliferation and neuronal differentiation of the grafts, enhanced their neuroprotective effects, and led to superior recovery compared to standard NSCs transplantation. Furthermore, administration of the Nrf2 agonist PTE synergized with Nrf2-overexpressed NSCs transplantation, resulting in augmented anti-inflammatory, antioxidant, and functional benefits.
conclusionThis study demonstrates that Nrf2 is a key regulator of NSCs proliferation and neuronal fate, both intrinsically and following transplantation. Furthermore, the combination of Nrf2-overexpressed NSCs transplantation and PTE administration synergistically amplified therapeutic outcomes, offering a promising combinatorial strategy to enhance neurorepair after ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.